JP2025516566A5 - - Google Patents

Info

Publication number
JP2025516566A5
JP2025516566A5 JP2024566275A JP2024566275A JP2025516566A5 JP 2025516566 A5 JP2025516566 A5 JP 2025516566A5 JP 2024566275 A JP2024566275 A JP 2024566275A JP 2024566275 A JP2024566275 A JP 2024566275A JP 2025516566 A5 JP2025516566 A5 JP 2025516566A5
Authority
JP
Japan
Prior art keywords
optionally substituted
substituted
groups
indole
alkyl groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024566275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025516566A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/062242 external-priority patent/WO2023217764A1/en
Publication of JP2025516566A publication Critical patent/JP2025516566A/ja
Publication of JP2025516566A5 publication Critical patent/JP2025516566A5/ja
Pending legal-status Critical Current

Links

JP2024566275A 2022-05-09 2023-05-09 アルポート症候群の治療における使用のためのnox阻害剤 Pending JP2025516566A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB202206759 2022-05-09
GB2206759.9 2022-05-09
PCT/EP2023/062242 WO2023217764A1 (en) 2022-05-09 2023-05-09 Nox inhibitors for use in the treatment of alport syndrome

Publications (2)

Publication Number Publication Date
JP2025516566A JP2025516566A (ja) 2025-05-30
JP2025516566A5 true JP2025516566A5 (cg-RX-API-DMAC7.html) 2026-05-18

Family

ID=86497898

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024566275A Pending JP2025516566A (ja) 2022-05-09 2023-05-09 アルポート症候群の治療における使用のためのnox阻害剤

Country Status (11)

Country Link
US (1) US20260021079A1 (cg-RX-API-DMAC7.html)
EP (1) EP4522162A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025516566A (cg-RX-API-DMAC7.html)
KR (1) KR20250008750A (cg-RX-API-DMAC7.html)
CN (1) CN119212698A (cg-RX-API-DMAC7.html)
AU (1) AU2023267259A1 (cg-RX-API-DMAC7.html)
CA (1) CA3252551A1 (cg-RX-API-DMAC7.html)
IL (1) IL316732A (cg-RX-API-DMAC7.html)
MX (1) MX2024013727A (cg-RX-API-DMAC7.html)
TW (1) TW202413355A (cg-RX-API-DMAC7.html)
WO (1) WO2023217764A1 (cg-RX-API-DMAC7.html)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2166010A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
UA116639C2 (uk) * 2012-10-09 2018-04-25 Рег'Юлес Терап'Ютікс Інк. Способи лікування синдрому альпорта
CN107743483B (zh) 2015-06-22 2022-01-28 埃科特莱茵药品有限公司 Nadph氧化酶4抑制剂
WO2017192304A1 (en) 2016-05-02 2017-11-09 Inception 1, Inc. Arylcarboxamides and uses thereof
BR112019023109A2 (pt) 2017-05-04 2020-05-26 Glenmark Pharmaceuticals S.A. Composto, composição farmacêutica e método para tratar uma doença, distúrbio, síndrome ou afecção mediada por nadph oxidase em um indivíduo
CN112384497A (zh) 2018-05-09 2021-02-19 格卢科克斯生物科技有限公司 具有选择性nox抑制活性的新型磺酰胺衍生物
CN114728168B (zh) * 2019-11-15 2024-04-09 吉利德科学公司 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途

Similar Documents

Publication Publication Date Title
RU2005117383A (ru) Производные фенилаланина в качестве ингибиторов дипептидилпептидазы для лечения или профилактики диабета
US11591336B2 (en) Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors
RU2424242C2 (ru) Азолопиримидины в качестве ингибиторов активности каннабиноидного рецептора 1
JP2004531473A5 (cg-RX-API-DMAC7.html)
JP2023513241A5 (cg-RX-API-DMAC7.html)
RU2015129538A (ru) Замещенные имидазопиридины в качестве ингибиторов hdm2
JP2019535664A5 (cg-RX-API-DMAC7.html)
RU2017134901A (ru) Соединения 1-циано-пирролидинов в качестве ингибиторов USP30
IL277579B (en) Piperidinone derivatives as mdm2 inhibitors for cancer therapy
JP2015522002A5 (cg-RX-API-DMAC7.html)
RU2018123779A (ru) Новые соединения
JP2007510689A5 (cg-RX-API-DMAC7.html)
JP2023525762A5 (cg-RX-API-DMAC7.html)
JP2015510938A5 (cg-RX-API-DMAC7.html)
JP2013508404A5 (cg-RX-API-DMAC7.html)
RU2008145504A (ru) Новое соединение пиперазина и его применение в качестве ингибитора hcv полимеразы
WO2019089835A1 (en) Diazanaphthalen-3-yl carboxamides and preparation and use thereof
EP2594270A2 (en) The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
CA2571627A1 (en) Substituted aryl-amine derivatives and methods of use
JP2010535799A5 (cg-RX-API-DMAC7.html)
JP2014511355A5 (cg-RX-API-DMAC7.html)
RU2009105829A (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ ITPKb
JP2021501216A5 (cg-RX-API-DMAC7.html)
IL310330A (en) Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling
KR20250081951A (ko) 금속 채널 활성화제를 포함하는 병용 요법